Solid Biosciences Aktie

Solid Biosciences has filed a prospectus supplement with the SEC for the potential sale of common shares of up to $200 million; the offering would be made under the existing universal shelf registration and an amended distribution agreement with Jefferies. The company, which most recently reported negative externally financed free cash flow of $173 million, had previously issued shares generating gross proceeds of about $85 million. In parallel, Solid reports pipeline progress: first participant treated in the Phase 3 IMPACT DUCHENNE study and continued development of the SGT-212 program; H.C. Wainwright raised its price target to $25 and reiterated a "Buy" rating. » More on de.investing.com

The European Commission has granted SGT-003 from Solid Biosciences orphan-drug designation for the treatment of Duchenne muscular dystrophy, following a positive opinion from the EMA committee for rare diseases. SGT-003 is a clinical-stage gene therapy featuring a microdystrophin construct and a proprietary muscle-specific capsid and is being evaluated in two multinational trials (Phase 1/2 INSPIRE and the randomized, placebo-controlled Phase 3 IMPACT). The designation brings benefits such as reduced fees, scientific support and up to ten years of market exclusivity; Solid has already received several special designations in the UK and the US. Investors reacted positively to the progress, and the stock rose strongly over the past year. » More on de.investing.com

Solid Biosciences reclassified Ilan Ganot, effective Friday at 4:00 p.m. ET, from a Class III director to a Class I director to achieve a balanced distribution of members across the board’s three classes. Ganot’s new term now expires at the 2028 annual meeting; he is therefore withdrawing from reelection in 2027 and is expected to be confirmed on an advisory basis at the 2026 annual meeting. The change does not affect his compensation and results in three members in Class I and three members in Class III. » More on de.investing.com